Author
Randy Strong
- Indexed works
- 42
- Total citations
- 11,407
- Active years
- 18
Collaborators
Works in the record
Nature 2009
Preprint · OA
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
PLoS ONE 2010
Open access · CC-BY
Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease
The Journals of Gerontology Series A 2010
Open access · OA
Rapamycin, But Not Resveratrol or Simvastatin, Extends Life Span of Genetically Heterogeneous Mice
Aging Cell 2012
Open access · OA
Rapamycin slows aging in mice
Aging Cell 2013
Open access · CC-BY
Rapamycin‐mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction
Aging Cell 2013
Open access · CC-BY
Acarbose, 17‐α‐estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males
PLoS ONE 2011
Open access · CC-BY
Inducing Autophagy by Rapamycin Before, but Not After, the Formation of Plaques and Tangles Ameliorates Cognitive Deficits
Aging Cell 2016
Open access · CC-BY
Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer
BMC Microbiology 2019
Open access · CC-BY
Changes in the gut microbiome and fermentation products concurrent with enhanced longevity in acarbose-treated mice
Aging Cell 2008
Open access · OA
Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice
Aging Cell 2007
Open access · OA
An aging Interventions Testing Program: study design and interim report
Neuroscience 2012
Preprint · OA
Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice
Journal of Cerebral Blood Flow & Metabolism 2013
Open access · OA
Chronic Rapamycin Restores Brain Vascular Integrity and Function Through NO Synthase Activation and Improves Memory in Symptomatic Mice Modeling Alzheimer’s Disease
AGE 2008
Open access · OA
Design of aging intervention studies: the NIA interventions testing program
EBioMedicine 2016
Open access · CC-BY
NIA Interventions Testing Program: Investigating Putative Aging Intervention Agents in a Genetically Heterogeneous Mouse Model
Aging Cell 2019
Open access · CC-BY
Acarbose improves health and lifespan in aging HET3 mice
JCI Insight 2020
Open access · CC-BY
Canagliflozin extends life span in genetically heterogeneous male but not female mice
Aging Cell 2021
Open access · CC-BY
17‐a‐estradiol late in life extends lifespan in aging UM‐HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex
Aging Cell 2009
Open access · OA
Lifespan extension in genetically modified mice
Aging Cell 2019
Open access · CC-BY
Glycine supplementation extends lifespan of male and female mice
Frontiers in Molecular Neuroscience 2014
Open access · CC-BY
Divergent tissue and sex effects of rapamycin on the proteasome-chaperone network of old mice
Science 2022
Preprint · OA
Sex- and age-dependent genetics of longevity in a heterogeneous mouse population
Aging Cell 2022
Open access · CC-BY
Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice
Aging 2014
Open access · CC-BY
Rapamycin-induced metabolic defects are reversible in both lean and obese mice
GeroScience 2023
Open access · CC-BY
Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002 (hydrogen sulfide donor), dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not significantly affect lifespan in either sex at the doses and schedules used
Aging 2015
Open access · CC-BY
Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus)
The Journals of Gerontology Series A 2010
Open access · OA
The Role of mTOR Signaling in Controlling Mammalian Life Span: What a Fungicide Teaches Us About Longevity
Clinical Colorectal Cancer 2020
Open access · CC-BY
Rapamycin Extends Life Span in ApcMin/+ Colon Cancer FAP Model
npj Parkinson s Disease 2023
Open access · CC-BY
DOPAL initiates αSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson’s disease
GeroScience 2022
Open access · CC-BY
Canagliflozin retards age-related lesions in heart, kidney, liver, and adrenal gland in genetically heterogenous male mice
GeroScience 2024
Preprint · OA
Lifespan effects in male UM-HET3 mice treated with sodium thiosulfate, 16-hydroxyestriol, and late-start canagliflozin
Elsevier eBooks 2021
Citation only
NIA Interventions Testing Program: A collaborative approach for investigating interventions to promote healthy aging
bioRxiv (Cold Spring Harbor Laboratory) 2020
Preprint · OA
Canagliflozin Extends Lifespan in Genetically Heterogeneous Male But Not Female Mice
GeroScience 2024
Open access · CC-BY
The Gehan test identifies life-extending compounds overlooked by the log-rank test in the NIA Interventions Testing Program: Metformin, Enalapril, caffeic acid phenethyl ester, green tea extract, and 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride
Aging Pathobiology and Therapeutics 2020
Open access · CC-BY
Sex-dependent lifespan extension of ApcMin/+ FAP mice by chronic mTOR inhibition
bioRxiv (Cold Spring Harbor Laboratory) 2018
Preprint · CC-BY
Changes in the gut microbiota and fermentation products associated with enhanced longevity in acarbose-treated mice
GeroScience 2025
Open access · CC-BY
Extension of lifespan by epicatechin, halofuginone and mitoglitazone in male but not female genetically heterogeneous mice
Nature Communications 2025
Open access · CC-BY
Deciphering the timing and impact of life-extending interventions: temporal efficacy profiler distinguishes early, midlife, and senescence phase efficacies
Elsevier eBooks 2015
Citation only
NIA Interventions Testing Program
bioRxiv (Cold Spring Harbor Laboratory) 2024
Preprint · CC-BY
Deciphering the Timing and Impact of Life-extending Interventions: Temporal Efficacy Profiler Distinguishes Early, Midlife, and Senescence Phase Efficacies
The Journals of Gerontology Series A 2025
Open access · OA
Sex as a major determinant of pro-longevity drug efficacy: a review of two decades of the NIA Interventions Testing Program
bioRxiv (Cold Spring Harbor Laboratory) 2025
Preprint · CC-BY